$SNWV
SANUWAVE Health, Inc. Stock $snwv

$snwv Overview Financials Valuation SEC Filings Company Website

2024 Q2 Form 10-Q Financial Statement

#000114036124025214 Filed on May 09, 2024

Income Statement

Concept	2024 Q2	2024 Q1
Revenue	$7.162M	$5.786M
YoY Change	53.2%	53.27%
Cost Of Revenue	$1.922M	$1.584M
YoY Change	59.9%	25.52%
Gross Profit	$5.240M	$4.202M
YoY Change	50.88%	67.21%
Gross Profit Margin	73.16%	72.62%
Selling, General & Admin	$2.873M	$4.907M
YoY Change	29.65%	17.65%
% of Gross Profit	54.83%	116.78%
Research & Development	$195.0K	$163.0K
YoY Change	40.29%	24.43%
% of Gross Profit	3.72%	3.88%
Depreciation & Amortization	$262.0K	$218.0K
YoY Change	2.34%	-15.83%
% of Gross Profit	5.0%	5.19%
Operating Expenses	$3.248M	$5.252M
YoY Change	27.77%	16.95%
Operating Profit	$1.992M	-$1.050M
YoY Change	113.96%	-46.92%
Interest Expense	-$66.00K	-$6.061M
YoY Change	-99.19%	-45.27%
% of Operating Profit	-3.31%
Other Income/Expense, Net	$4.569M	-$3.478M
YoY Change	-155.77%	-68.67%
Pretax Income	$6.561M	-$4.528M
YoY Change	-190.35%	-65.38%
Income Tax
% Of Pretax Income
Net Earnings	$6.561M	-$4.528M
YoY Change	-190.35%	-65.38%
Net Earnings / Revenue	91.61%	-78.26%
Basic Earnings Per Share	$0.01	$0.00
Diluted Earnings Per Share	$0.00	$0.00
COMMON SHARES
Basic Shares Outstanding	1.146B	1.141B
Diluted Shares Outstanding	1.388B shares	1.162B

Balance Sheet

Concept	2024 Q2	2024 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$2.460M	$2.936M
YoY Change	640.96%	2669.81%
Cash & Equivalents	$2.460M	$2.936M
Short-Term Investments
Other Short-Term Assets	$379.0K	$2.426M
YoY Change	-81.52%	553.91%
Inventory	$2.731M	$2.461M
Prepaid Expenses
Receivables	$3.154M	$3.008M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$8.724M	$10.83M
YoY Change	42.99%	139.78%
LONG-TERM ASSETS
Property, Plant & Equipment	$947.0K	$975.0K
YoY Change	-9.81%	28.63%
Goodwill	$7.260M	$7.260M
YoY Change	0.0%	0.0%
Intangibles	$4.082M	$4.258M
YoY Change	-14.71%	-14.19%
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$12.29M	$12.49M
YoY Change	-6.16%	-3.75%
TOTAL ASSETS
Total Short-Term Assets	$8.724M	$10.83M
Total Long-Term Assets	$12.29M	$12.49M
Total Assets	$21.01M	$23.32M
YoY Change	9.46%	33.3%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$3.891M	$5.062M
YoY Change	-19.92%	-3.84%
Accrued Expenses	$4.794M	$6.849M
YoY Change	-24.52%	-19.89%
Deferred Revenue	$130.0K	$107.0K
YoY Change	94.03%	72.58%
Short-Term Debt	$23.92M	$18.91M
YoY Change	48.38%	26.1%
Long-Term Debt Due	$6.407M	$10.00M
YoY Change	-75.41%	-59.28%
Total Short-Term Liabilities	$59.97M	$70.18M
YoY Change	-24.36%	-0.66%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$654.0K	$735.0K
YoY Change	-10.41%	20.69%
Total Long-Term Liabilities	$654.0K	$735.0K
YoY Change	-13.72%	15.38%
TOTAL LIABILITIES
Total Short-Term Liabilities	$59.97M	$70.18M
Total Long-Term Liabilities	$654.0K	$735.0K
Total Liabilities	$60.62M	$70.92M
YoY Change	-24.26%	-0.52%
SHAREHOLDERS EQUITY
Retained Earnings	-$218.0M	-$224.6M
YoY Change	1.6%	8.32%
Common Stock	$1.182M	$1.140M
YoY Change	110.32%	105.04%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$39.61M	-$47.60M
YoY Change
Total Liabilities & Shareholders Equity	$21.01M	$23.32M
YoY Change	9.46%	33.3%

Cashflow Statement

Concept	2024 Q2	2024 Q1
OPERATING ACTIVITIES
Net Income	$6.561M	-$4.528M
YoY Change	-190.35%	-65.38%
Depreciation, Depletion And Amortization	$262.0K	$218.0K
YoY Change	2.34%	-15.83%
Cash From Operating Activities	-$668.0K	$1.100M
YoY Change	-20.85%	-396.5%
INVESTING ACTIVITIES
Capital Expenditures	$92.00K	$114.0K
YoY Change	-39.07%	533.33%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$92.00K	-$114.0K
YoY Change	-39.07%	533.33%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	274.0K	42.00K
YoY Change	-86.83%	-106.42%
NET CHANGE
Cash From Operating Activities	-668.0K	1.100M
Cash From Investing Activities	-92.00K	-114.0K
Cash From Financing Activities	274.0K	42.00K
Net Change In Cash	-486.0K	1.139M
YoY Change	-144.79%	-208.79%
FREE CASH FLOW
Cash From Operating Activities	-$668.0K	$1.100M
Capital Expenditures	$92.00K	$114.0K
Free Cash Flow	-$760.0K	$986.0K
YoY Change	-23.62%	-353.47%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2023Q4	snwv	Operating Lease And Finance Lease Liability Noncurrent OperatingLeaseAndFinanceLeaseLiabilityNoncurrent	492000
CY2024Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	6849000
CY2023Q1	us-gaap	Revenues Revenues	3775000
CY2024Q1	us-gaap	Cost Of Revenue CostOfRevenue	1584000
CY2023Q1	us-gaap	Cost Of Revenue CostOfRevenue	1262000
CY2024Q1	us-gaap	Gross Profit GrossProfit	4202000
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2024Q1	us-gaap	Preferred Stock Value PreferredStockValue	0
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue	0
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2024Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2024Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	2500000000
CY2024Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1140559527
CY2024Q1	us-gaap	Common Stock Value CommonStockValue	1140000
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	175842000
CY2024Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-224577000
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-220049000
CY2024Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	0
CY2023Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2759000
CY2024Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	1232000
CY2024Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	163000
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	131000
CY2024Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	182000
CY2024Q1	us-gaap	Operating Expenses OperatingExpenses	5252000
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	4491000
CY2024Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-1050000
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-1978000
CY2024Q1	snwv	Change In Fair Value Of Derivative Liabilities ChangeInFairValueOfDerivativeLiabilities	2501000
CY2023Q1	snwv	Change In Fair Value Of Derivative Liabilities ChangeInFairValueOfDerivativeLiabilities	6797000
CY2024Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-3478000
CY2023Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-11102000
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-13084000
CY2024Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0
CY2024Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.02
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.02
CY2024Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1162250687
CY2024Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1162250687
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	575028811
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	575028811
CY2024Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2023Q4	us-gaap	Goodwill Goodwill	7260000
CY2023Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	347000
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-43178000
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1797000
CY2024Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	3008000
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	3314000
CY2024Q1	us-gaap	Inventory Net InventoryNet	2461000
CY2024Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2426000
CY2024Q1	us-gaap	Assets Current AssetsCurrent	10831000
CY2023Q4	us-gaap	Assets Current AssetsCurrent	9784000
CY2024Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	975000
CY2024Q1	us-gaap	Assets Assets	23324000
CY2023Q4	us-gaap	Assets Assets	22416000
CY2024Q1	us-gaap	Senior Notes Current SeniorNotesCurrent	18910000
CY2023Q4	us-gaap	Senior Notes Current SeniorNotesCurrent	18278000
CY2024Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	5062000
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	5705000
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	5999000
CY2024Q1	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	735000
CY2023Q4	us-gaap	Liabilities Liabilities	65594000
CY2024Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2936000
CY2024Q1	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	1237000
CY2023Q4	us-gaap	Inventory Net InventoryNet	2951000
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1722000
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	938000
CY2024Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	4258000
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	4434000
CY2024Q1	us-gaap	Goodwill Goodwill	7260000
CY2024Q1	us-gaap	Assets Noncurrent AssetsNoncurrent	12493000
CY2023Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	12632000
CY2024Q1	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	340000
CY2024Q1	us-gaap	Liabilities Liabilities	70919000
CY2024Q1	us-gaap	Revenues Revenues	5786000
CY2023Q1	us-gaap	Gross Profit GrossProfit	2513000
CY2024Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3675000
CY2023Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	1412000
CY2023Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	189000
CY2024Q1	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	102000
CY2023Q1	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	27000
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-4528000
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-13080000
CY2024Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	111000
CY2023Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-4000
CY2024Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-4417000
CY2024Q1	snwv	Factoring Liabilities Current FactoringLiabilitiesCurrent	1561000
CY2023Q4	snwv	Factoring Liabilities Current FactoringLiabilitiesCurrent	1490000
CY2024Q1	snwv	Warrant Liability Current WarrantLiabilityCurrent	19818000
CY2023Q4	snwv	Warrant Liability Current WarrantLiabilityCurrent	14447000
CY2024Q1	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	107000
CY2023Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	92000
CY2024Q1	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	969000
CY2023Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	947000
CY2024Q1	us-gaap	Liabilities Current LiabilitiesCurrent	70184000
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	64755000
CY2024Q1	snwv	Operating Lease And Finance Lease Liability Noncurrent OperatingLeaseAndFinanceLeaseLiabilityNoncurrent	395000
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2024Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	2500000000
CY2024Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1140559527
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	1140000
CY2024Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	175842000
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-111000
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	-47595000
CY2024Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	23324000
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	22416000
CY2024Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-weight: bold; font-style: italic;">Estimates</span> – These condensed consolidated financial statements have been prepared in accordance with U.S. GAAP. Because a precise determination of assets and liabilities, and correspondingly revenues and expenses, depend on future events, the preparation of condensed consolidated financial statements for any period necessarily involves the use of estimates and assumptions. Actual amounts may differ from these estimates. These condensed consolidated financial statements have, in management’s opinion, been properly prepared within reasonable limits of materiality and within the framework of the accounting policies summarized herein.</div> <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/> </div> <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Significant estimates include the recording of allowances for credit losses, the net realizable value of inventory, fair value of goodwill and other intangible assets, the determination of the valuation allowances for deferred taxes, litigation contingencies, and the estimated fair value of financial instruments, including warrants and embedded conversion options.</div>
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000
CY2024Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000
CY2024Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-13080000
CY2024Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	218000
CY2023Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	259000
CY2024Q1	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	147000
CY2023Q1	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	156000
CY2024Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	2501000
CY2023Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	6797000
CY2024Q1	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	1553000
CY2023Q1	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	1931000
CY2024Q1	us-gaap	Financing Receivable Accrued Interest Writeoff FinancingReceivableAccruedInterestWriteoff	955000
CY2023Q1	us-gaap	Financing Receivable Accrued Interest Writeoff FinancingReceivableAccruedInterestWriteoff	1365000
CY2024Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-152000
CY2023Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-906000
CY2024Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-490000
CY2023Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	203000
CY2023Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-195000
CY2024Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-643000
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	864000
CY2024Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-20000
CY2023Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	450000
CY2024Q1	us-gaap	Increase Decrease In Derivative Liabilities IncreaseDecreaseInDerivativeLiabilities	-22000
CY2023Q1	us-gaap	Increase Decrease In Derivative Liabilities IncreaseDecreaseInDerivativeLiabilities	-11000
CY2024Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	1100000
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-371000
CY2023Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	18000
CY2024Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-114000
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-18000
CY2024Q1	snwv	Payments To Factoring Agent Net PaymentsToFactoringAgentNet	-71000
CY2023Q1	snwv	Payments To Factoring Agent Net PaymentsToFactoringAgentNet	610000
CY2024Q1	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	29000
CY2024Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	42000
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-654000
CY2024Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	111000
CY2023Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-4000
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	1139000
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-1047000
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1797000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1153000
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2936000
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	106000
CY2024Q1	us-gaap	Interest Paid Net InterestPaidNet	971000
CY2023Q1	us-gaap	Interest Paid Net InterestPaidNet	908000
CY2024Q1	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	4584000
CY2023Q1	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	0
CY2024Q1	snwv	Common Shares Issued For Advisory Shares CommonSharesIssuedForAdvisoryShares	0
CY2023Q1	snwv	Common Shares Issued For Advisory Shares CommonSharesIssuedForAdvisoryShares	302000
CY2024Q1	dei	Amendment Flag AmendmentFlag	false
CY2024Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2024Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
CY2024Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2024Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001417663
CY2024Q1	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2024Q1	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q1	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q1	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2024Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2024Q1	dei	Document Type DocumentType	10-Q
CY2024Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2024Q1	dei	Document Period End Date DocumentPeriodEndDate	2024-03-31
CY2024Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2024Q1	dei	Entity File Number EntityFileNumber	000-52985
CY2024Q1	dei	Entity Registrant Name EntityRegistrantName	SANUWAVE Health, Inc.
CY2024Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
CY2024Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	20-1176000
CY2024Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	11495 Valley View Road
CY2024Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Eden Prairie
CY2024Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	MN
CY2024Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	55344
CY2024Q1	dei	City Area Code CityAreaCode	952
CY2024Q1	dei	Local Phone Number LocalPhoneNumber	656-1029
CY2024Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2024Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2024Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2024Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2024Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2024Q1	dei	Entity Shell Company EntityShellCompany	false
CY2024Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	1145974342
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	1237000
CY2023Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	839000
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1140559527
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1140559527
CY2024Q1	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	2790000
CY2023Q1	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	0
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-43178000
CY2024Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	111000
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-4528000
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	-47595000
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-41010000
CY2023Q1	snwv	Shares Issued For Settlement Of Debt And Warrants SharesIssuedForSettlementOfDebtAndWarrants	303000
CY2023Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-4000
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-13080000
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-53791000
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-4528000
CY2024Q1	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-105000
CY2023Q1	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0
CY2024Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-192000
CY2024Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	114000
CY2023Q1	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	44000
CY2024Q1	snwv	Warrants Issued In Conjunction With Convertible Promissory Notes WarrantsIssuedInConjunctionWithConvertiblePromissoryNotes	2784000
CY2023Q1	snwv	Warrants Issued In Conjunction With Convertible Promissory Notes WarrantsIssuedInConjunctionWithConvertiblePromissoryNotes	0
CY2024Q1	us-gaap	Nature Of Operations NatureOfOperations	<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"> <table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"> <tr> <td style="width: 27pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;"> <div>1.</div> </td> <td style="width: auto; vertical-align: top; text-align: justify;"> <div style="color: rgb(0, 0, 0); font-weight: bold;">Nature of the Business and Basis of Presentation</div> </td> </tr> </table> </div> <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"> <br/> </div> <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">SANUWAVE Health, Inc. and subsidiaries (“SANUWAVE” or the “Company”) is focused on the commercialization of its patented noninvasive and biological response activating medical systems for the repair and regeneration of skin, musculoskeletal tissue, and vascular structures.</div> <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/> </div> <div style="text-align: justify; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-weight: bold; font-style: italic;">Basis of Presentation – </span>The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 8-03 of Regulation S-X. Accordingly, these condensed consolidated financial statements do not include all the information and disclosures required by U.S. GAAP for comprehensive financial statements. </div> <div style="text-align: justify; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"> <br/> </div> <div style="text-align: justify; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">The financial information as of March 31, 2024, and for the three months ended March 31, 2024, and 2023 is unaudited; however, in the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair statement have been included. Operating results for the three months ended March 31, 2024, are not necessarily indicative of the results that may be expected for any other interim period or for the year ending December 31, 2024.</div> <div style="font-family: 'Times New Roman'; font-size: 10pt;"> </div> <div style="text-align: justify; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">The condensed consolidated balance sheet on December 31, 2023, has been derived from the audited consolidated financial statements at that date but does not include all the information and disclosures required by U.S. GAAP for comprehensive financial statements. These financial statements should be read in conjunction with the Company’s December 31, 2023, Annual Report on Form 10-K filed with the SEC on March 21, 2024 (the “2023 Annual Report”).</div>
CY2024Q1	us-gaap	Deferred Offering Costs DeferredOfferingCosts	1600000
CY2024Q1	snwv	Class Of Warrant Or Right Exercise Price ClassOfWarrantOrRightExercisePrice	0.01
CY2024Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1162251000
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	575029000
CY2024Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1728174000
CY2023Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1830385000
CY2024Q1	snwv	Accrued Registration Penalties Current AccruedRegistrationPenaltiesCurrent	1583000
CY2023Q4	snwv	Accrued Registration Penalties Current AccruedRegistrationPenaltiesCurrent	1583000
CY2024Q1	snwv	Accrued License Fees Current AccruedLicenseFeesCurrent	892000
CY2023Q4	snwv	Accrued License Fees Current AccruedLicenseFeesCurrent	892000
CY2024Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1072000
CY2023Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	942000
CY2024Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2449000
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2298000
CY2024Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	853000
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	284000
CY2024Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	6849000
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	5999000
CY2024Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3 FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3	0
CY2024Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3 FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3	0
CY2023Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3 FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3	0
CY2023Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3 FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3	0
CY2024Q1	snwv	Exchange Ratio ExchangeRatio	0.003
CY2024Q1	snwv	Probability Of Closing Merger ProbabilityOfClosingMerger	0.90
CY2024Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	5684000
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	3492000
CY2024Q1	us-gaap	Operating Lease Lease Income OperatingLeaseLeaseIncome	102000
CY2023Q1	us-gaap	Operating Lease Lease Income OperatingLeaseLeaseIncome	283000
CY2024Q1	us-gaap	Revenues Revenues	5786000
CY2023Q1	us-gaap	Revenues Revenues	3775000
CY2024Q1	us-gaap	Loss Contingency Disclosures LossContingencyDisclosures	<table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"> <tr> <td style="width: 27pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">14.</td> <td style="width: auto; vertical-align: top; text-align: justify;"> <div style="color: rgb(0, 0, 0); font-weight: bold;">Commitments and Contingencies</div> </td> </tr> </table> <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; font-style: normal; font-variant: normal; text-transform: none;">In the ordinary course of business, the Company from time to time becomes involved in various legal proceedings involving a variety of matters. The Company does not believe there are any pending legal proceedings that will have a material adverse effect on the Company’s business, consolidated financial position, results of operations, or cash flows. However, the outcome of such legal matters is inherently unpredictable and subject to significant uncertainties. The Company expenses legal fees in the period in which they are incurred.</div> <div><span style="font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0);"> </div> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; font-style: normal; font-variant: normal; text-transform: none; text-align: justify;"> <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; letter-spacing: normal; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; font-weight: bold; font-style: italic;">Termination Agreement</span><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"> – In February 2024, the Company entered into a termination agreement with an advisor to agree on termination fees owed with respect to a previous engagement agreement. The company agreed to a contingent payment of $670 thousand upon the closure of the Merger disclosed in note 4.</span></div> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; font-style: normal; font-variant: normal; text-transform: none;"> <br/> </div> <div><span style="font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div> <div style="text-align: justify; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-weight: normal; font-style: normal; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="font-weight: bold; font-style: italic;">Acquisition dispute</span></span> –<span style="font-weight: normal; font-style: normal; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> In May 2021, the Company received notification alleging that it is not in compliance with the license agreement with Celularity entered into in connection with the acquisition of the UltraMIST assets. The Company has responded and asserted that the Company is not in breach and that the supplier has breached various agreements. It is too early to determine the outcome of this matter. Any potential impact on the Company cannot be fully determined at this time and there is no guarantee that the dispute will be resolved in a manner beneficial to the Company.</span></div>

Files In Submission

Name	View Source	Status
snwv-20240331_cal.xml	Edgar Link	unprocessable
0001140361-24-025214-index-headers.html	Edgar Link	pending
0001140361-24-025214-index.html	Edgar Link	pending
0001140361-24-025214.txt	Edgar Link	pending
0001140361-24-025214-xbrl.zip	Edgar Link	pending
ef20026302_10q.htm	Edgar Link	pending
ef20026302_ex31-1.htm	Edgar Link	pending
ef20026302_ex31-2.htm	Edgar Link	pending
ef20026302_ex32-1.htm	Edgar Link	pending
ef20026302_ex32-2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
snwv-20240331.xsd	Edgar Link	pending
snwv-20240331_def.xml	Edgar Link	unprocessable
snwv-20240331_lab.xml	Edgar Link	unprocessable
snwv-20240331_pre.xml	Edgar Link	unprocessable
ef20026302_10q_htm.xml	Edgar Link	completed

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$SNWV
SANUWAVE Health, Inc. Stock $snwv

2024 Q2 Form 10-Q Financial Statement

#000114036124025214 Filed on May 09, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SNWV SANUWAVE Health, Inc. Stock $snwv

2024 Q2 Form 10-Q Financial Statement

#000114036124025214 Filed on May 09, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SNWV
SANUWAVE Health, Inc. Stock $snwv